16,614 Shares in IQVIA Holdings Inc. $IQV Acquired by Empowered Funds LLC

Empowered Funds LLC purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, Holdings Channel.com reports. The firm purchased 16,614 shares of the medical research company’s stock, valued at approximately $3,210,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of IQVIA during the 2nd quarter worth approximately $2,811,292,000. Geode Capital Management LLC boosted its holdings in IQVIA by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock worth $982,272,000 after purchasing an additional 24,453 shares during the last quarter. Boston Partners grew its position in IQVIA by 14.9% in the fourth quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock valued at $923,276,000 after purchasing an additional 530,672 shares in the last quarter. JPMorgan Chase & Co. increased its stake in IQVIA by 16.2% in the 4th quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock valued at $856,468,000 after buying an additional 528,753 shares during the last quarter. Finally, Invesco Ltd. increased its stake in IQVIA by 15.3% in the 3rd quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company’s stock valued at $526,891,000 after buying an additional 367,204 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other IQVIA news, insider Eric Sherbet sold 5,000 shares of the firm’s stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total value of $1,245,800.00. Following the sale, the insider owned 20,999 shares of the company’s stock, valued at approximately $5,232,110.84. This trade represents a 19.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider W Richard Staub sold 5,500 shares of the stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the transaction, the insider directly owned 13,312 shares of the company’s stock, valued at $3,097,436.16. This trade represents a 29.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 12,913 shares of company stock valued at $3,098,793 in the last 90 days. 1.70% of the stock is owned by corporate insiders.

IQVIA Stock Down 1.1%

IQVIA stock opened at $258.39 on Wednesday. The company’s 50-day moving average price is $225.75 and its two-hundred day moving average price is $190.73. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The stock has a market cap of $42.53 billion, a P/E ratio of 32.06, a P/E/G ratio of 2.23 and a beta of 1.18. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $265.25.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. During the same quarter last year, the company earned $2.81 earnings per share. The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, analysts expect that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its Board of Directors has authorized a share buyback program on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on IQV. BMO Capital Markets raised their price objective on IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. TD Cowen upped their target price on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Robert W. Baird increased their price target on IQVIA from $252.00 to $287.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Royal Bank Of Canada boosted their price target on IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Finally, HSBC reiterated a “buy” rating and set a $240.00 price objective on shares of IQVIA in a research note on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $241.88.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.